CIP2A Antibody (2G10) [Janelia Fluor® 646]

• Reactivity: Hu, Mu, Rt, Pm
• Applications: WB, Flow, ICC/IF, IHC, Mycoplasma
• Clone: 2G10
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Janelia Fluor 646

CIP2A Antibody (2G10) [Janelia Fluor® 646] Summary

• Description: This conjugate is made on demand and is not held in inventory. Each order represents a unique lot. All conjugates are generated using validated conjugation protocols and meet strict degree of labeling (F/P) specifications; additional information is available upon request. The antibody concentration is provided on the individual product label.
  
  For specialized conjugation needs, like large quantities, specific concentrations, and defined F/P ratios, bulk and custom antibody conjugation services are available.
• Immunogen: A synthetic peptide made to a C-terminal portion of the human CIP2A protein. [UniProt# Q8TCG1]
• Epitope: A 300 amino acid portion of the C-terminus.
• Localization: Cytoplasmic
• Isotype: IgG2b Kappa
• Clonality: Monoclonal
• Host: Mouse
• Gene: CIP2A
• Purity: Protein G purified

Applications/Dilutions

• Dilutions:
  • Flow Cytometry
  • Immunocytochemistry/ Immunofluorescence
  • Immunohistochemistry
  • Immunohistochemistry-Paraffin
  • Knockdown Validated
  • Western Blot
• Application Notes: Recommended applications are based on validated applications from the unconjugated base product NB110-59722. This conjugated antibody is not kept in inventory and is made to order using validated conjugation protocols.

Reactivity Notes

Other species have not been tested.

Packaging, Storage & Formulations

• Storage: Store at 4C in the dark.
• Buffer: 50mM Sodium Borate
• Preservative: 0.05% Sodium Azide
• Purity: Protein G purified

Notes

Sold under license from the Howard Hughes Medical Institute, Janelia Research Campus.

Alternate Names for CIP2A Antibody (2G10) [Janelia Fluor® 646]

• Cancerous inhibitor of PP2A
• CIP2A
• FLJ12850
• KIAA1524
• MGC163436
• p90 autoantigen
• p90
• protein CIP2A

Background

Inhibition of protein phosphatase 2A (PP2A) activity has been identified as a prerequisite for the transformation of human cells. The protein, designated Cancerous Inhibitor of PP2A (CIP2A), interacts directly with the oncogenic transcription factor c-Myc, inhibits PP2A activity toward c-Myc serine 62 (S62), and thereby prevents c-Myc proteolytic degradation. In addition to its function in c-Myc stabilization, CIP2A promotes anchorage-independent cell growth and in vivo tumor formation. The oncogenic activity of CIP2A is demonstrated by transformation of human cells by overexpression of CIP2A. Importantly, CIP2A is overexpressed in two common human malignancies, head and neck squamous cell carcinoma (HNSCC) and colon cancer.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: CIP2A